In this study we have used two new monoclonal antibodies, designated LJP5 and LJP9, as well as a previously described one, AP2, all specific for the platelet membrane glycoprotein (GP)IIb/IIIa complex. None of them reacted with dissociated GPIIb or GPIIIa. The monovalent Fab fragment of both LJP5 and LJP9 bound to unstimulated platelets in a saturable manner, but binding was markedly decreased after platelets had been incubated at 37 degrees C in the absence of added extracellular calcium. The binding of LJP9 was not affected by AP2, but was blocked by excess LJP5. On the contrary, the binding of LJP5 was blocked in the presence of both AP2 and LJP9. Thus, these antibodies bound to distinct epitopes of GPIIb/IIIa. At saturation, the binding to unstimulated platelets was between 2.41 and 10.9 X 10(4) molecules/platelet for LJP5 and between 3.47 and 9.1 X 10(4) molecules/platelet for LJP9 (range of 11 and 10 experiments, respectively). Binding increased up to 50% after thrombin stimulation. The estimated association constant, Ka, was 2.7 X 10(7) M-1 for LJP5 and 3.85 X 10(7) M-1 for LJP9. Both LJP5 and LJP9 partially inhibited the association of 45Ca2+ with the surface of unstimulated platelets. Moreover, both antibodies blocked the binding of von Willebrand factor (vWF) to stimulated platelets, whereas only LJP9, but not LJP5, blocked fibrinogen binding. UP5. On the contrary, the binding of LJP5 was blocked in the presence of both AP2 and LJP9. Thus, these antibodies bound to distinct epitopes of GPIIb/IIIa. At saturation, the binding to unstimulated platelets was between 2.41 and 10.9 X 104 molecules/platelet for LJP5 and between 3.47 and 9.1 X 104 molecules/platelet for LJP9 (range of 11 and 10 experiments, respectively). Binding increased up to 50% after thrombin stimulation. The estimated association constant, K., was 2.7 X 107 M-1 for LJP5 and 3.85 X 107 M-1 for LJP9. Both UP5 and 1JP9 partially inhibited the association of 45Ca2W with the surface of unstimulated platelets. Moreover, both antibodies blocked the binding of von Willebrand factor (vWF) to stimulated platelets, whereas only UJP9, but not UP5, blocked fibrinogen binding. LJP9 was also a potent inhibitor of platelet aggregation, whereas UP5 was without effect in this regard. The results of the present study demonstrate that independent modulation of vWF and fibrinogen binding to stimulated platelets can be attained with monoclonal antibodies directed against distinct epitopes of GPIIb/IIIa.
Introduction
The multimeric glycoprotein von Willebrand factor (vWF)' plays an essential role in the formation of a normal platelet plug at This work was presented in part at the 26th Meeting of the American Society of Hematology, 1-4 December 1984, Miami, FL and was published as an abstract (1984. Blood. 64[Suppl. 11:249a).
sites of vascular injury, but the exact molecular mechanisms underlying this function have yet to be unraveled (1) . Its specific binding to the platelet membrane glycoprotein (GP)Ib can be experimentally demonstrated using ristocetin (2, 3) or after desialylation of the molecule (4). More recently, it has been shown that thrombin, as well as other platelet agonists, also induce the binding of vWF to platelets (5, 6) . In this case, however, binding occurs at site(s) localized on the GPIIb/IIIa complex (2, 7) .
Fibrinogen is also essential for normal platelet aggregation and is thought to function by interacting with a specific receptor on GPIIb/IIIa (8, 9) . Fibrinogen can inhibit vWF binding to stimulated platelets (10) (11) (12) (13) , and the reverse also applies (10) . Moreover, synthetic peptides representing the carboxyl terminal of the y chain of fibrinogen, and much smaller than the parent molecule, can block the binding of both fibrinogen and vWF to GPIIb/IIIa (10, 14) , thus suggesting that the site involved is very similar, if not identical, for both ligands. Similar conclusions have been reached based on experiments with monoclonal antibodies that inhibited the binding of both fibrinogen and vWF, as well as fibronectin and thrombospondin, to thrombin-stimulated platelets (15). Hence, the concept has been developed that a common binding site on GPIIb/IIIa may mediate the interaction ofa family ofadhesive glycoproteins with stimulated platelets.
In order to test the latter hypothesis, we have undertaken the characterization ofa group of monoclonal antibodies directed against GPIIb/IIIa to see whether they all behaved similarly in inhibiting the binding of vWF and fibrinogen to platelets. For these studies, the smallest possible immunological probe was used, namely the monovalent Fab fragment derived from purified monoclonal IgG. We have obtained evidence that blocking distinct epitopes of the GPIIb/IIIa complex has distinct effects on the binding of vWF and fibrinogen to stimulated platelets.
Methods
Monoclonal antibody and Fab fragment preparation. Monoclonal antibodies against human platelet membrane glycoproteins were produced by immunizing BALB/c mice with intraperitoneal injections of washed platelet suspensions. These were prepared by gel filtration of plateletrich plasma through Sepharose CL 2B (Pharmacia Fine Chemicals, Piscataway, NJ) as previously described (2) , the only difference being that no albumin was used in the eluting buffer. The first injection consisted of 108 platelets in Freund's complete adjuvant. Two boosters of 108 and 1.5 X 108 platelets, respectively, in Freund's incomplete adjuvant were given at l-wk intervals. A final booster of 3 X 108 platelets without adjuvant was given 4 d before fusion. Mouse spleen cells were fused with mouse plasmacytoma cells at a ratio of 6:1. The two new antibodies described in this report, designated UP5 and LJP9, were derived from separate fusions. WP5 was obtained using P3X63-Ag 8.653 plasmacytoma cells, and UP9 using NS-1 cells. Fusion and growth ofhybridomas were performed using standard technology, as previously described ( 16) . Positive hybridomas producing anti-platelet antibodies were selected by digestion mixture was Fab/c, as well as undigested IgG, in accordance with the previously reported fragmentation pattern of mouse IgG2b (24) . AP2 (IgG 1) was too susceptible to pepsin digestion for Fab to be obtained in satisfactory quantities. Therefore, this IgG was digested with 5% papain (wt/wt) (Sigma) in 0.15 M phosphate buffer, pH 7, for 90 min at 37°C (25) . The mixture contained also 0.01 M cysteine and 0.002 M EDTA. The reaction was terminated by addition of 0.05 M iodoacetamide for 60 min at room temperature. This achieved, at the same time, S-carboxymethylation of Fab. Undigested Fc was separated from the mixture by passage through a Protein A-Sepharose column to which Fab did not bind. All Fab preparations were finally concentrated to between 1.5 and 4 mg/ml by ultrafiltration and extensively dialyzed against 0.02 M Tris, 0.15 M NaCl buffer, pH 7.4. Polyacrylamide gel electrophoresis (10% acrylamide with 5% cross-linking) in the presence of sodium dodecyl sulfate (SDS) (26) was used to assess the purity of each Fab preparation. Protein concentration was measured by the method of Lowry et al. (27) , using bovine serum albumin (Sigma Chemical Co.) and bovine IgG (Miles Scientific, Naperville, IL) as standards, or by light absorption at 280 mm assuming E`= 14.2.
Preparation ofwashed platelet suspensions. Washed platelets for aggregation and binding studies were prepared from blood drawn through 19-gauge needles into polypropylene syringes and transferred into polypropylene tubes containing 1/6th final volume of acid/citrate/dextrose (ACD), pH 4.5. Platelet-rich plasma was obtained as previously described (2) . Platelets were routinely washed free of plasma constituents by the albumin density-gradient technique of Walsh et al. (28) , with minor modifications. These consisted in the addition ofapyrase (grade III, Sigma) to the platelet-rich plasma (5 U/ml based on 5'-ATPase activity) and to the buffer used in the two subsequent washes (I and 0.2 U/ml, respectively). The platelets were finally resuspended in Tyrode's buffer, pH 7.4, and counted before use (2) . Platelet suspensions devoid of divalent cations were obtained as described by Marguerie et al. (29) . The calcium content of the buffers used for the latter procedure was <5 AM, as determined by absorption spectrophotometry.
Surface labeling ofplatelet membrane glycoproteins. Blood was drawn in ACD and platelet-rich plasma prepared as described (2 (30) . After overnight incubation at 4°C, the plates were washed and the monoclonal antibody to be tested (usually culture fluid supernatant or ascites) was added to several wells (usually four), followed by incubation for 4 h at room temperature. After washing, blocking of unreacted sites on the plastic, and additional washing, 100
Al of radiolabeled platelet membrane proteins, prepared as described above, was added to each well and incubated for 4 h at room temperature. The plates were then washed four times with phosphate buffer containing 0.5% Triton and 0.1% SDS, after which 50 Al of hot (boiling) 0.01 M phosphate buffer, pH 7.0, containing 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, and 0.05% bromophenol blue was added to each well.
After incubation for 5 min, the samples from wells containing the same monoclonal antibody were pooled, boiled for an additional 5 min, and then analyzed in SDS-polyacrylamide gel electrophoresis.
Crossed immunoelectrophoresis ofplatelet membrane glycoproteins.
This was performed as previously described (31), using 100 Ag of platelet lysate in the first dimension and running the second dimension against polyspecific rabbit anti-human platelet antibody (purified IgG). Purified
IgG of the monoclonal antibody to be tested (50 Ag) was incorporated in the intermediate gel of the second dimension. After electrophoresis, gels were washed twice and then incubated with at least 4 X 106 cpm (=-80 Ag) of '25I-labeled affinity-purified rabbit anti-mouse IgG (Zymed Laboratories, Inc., San Francisco, CA). Following an 18-h incubation at ambient temperature in a humidified chamber, the gels were washed, dried and stained with Coomassie blue-R (Sigma Chemical Co.) as previously described (31) . Autoradiography was accomplished by storing dried gels in the dark for 4-24 h between a Kodak X-Omat R film and a duPont Cronex Lightning Plus screen (E. I. du Pont de Nemours, Inc., Wilmington, DE), at ambient temperature. Aggregation studies. Platelet-rich plasma for aggregation studies was prepared as described above, the only difference being that blood was anticoagulated with 0.1 1 M trisodium citrate in a proportion of 9:1. For these experiments, the platelet count in platelet-rich plasma or washed platelet suspensions was adjusted so that the final count in the experimental mixture was 2 X 108/ml. The effect of monoclonal Fab on platelet aggregation was tested by incubating the Fab and the platelets for 3 min at 37°C, without stirring, before transferring to the stirred cell of the aggregometer and adding the agonist. When washed platelets were used, purified fibrinogen (300 Ag/ml, 8.8 X 10-7 M) and CaCl2 (2 mM) were added to the mixture together with the antibody. Aggregation was revon Willebrand Factor and Fibrinogen Receptor on Platelets corded as increase in light transmission through the mixture using a Lumiaggregometer (Chrono Log Corporation, Havertown, PA) and a dual-channel recorder (Kipp and Zonen, Bohemia, NY).
Purification offibrinogen and vWF. Fibrinogen was purified from blood collected into 'Ao volume of0.1 1 M trisodium citrate anticoagulant, containing 1 M E-aminocaproic acid and 0.365 mg/ml of Aprotonin (Sigma Chemical Co.), by means ofprecipitation with polyethylene glycol 1,000 (Sigma Chemical Co.) as previously described (32) . Analysis of the purified fibrinogen by 7.5% polyacrylamide (5% cross-linking) slab gel electrophoresis in the presence ofSDS and under reducing conditions showed the characteristic Aa, Bfl, and -y chains (33) . Absence of vWF and fibronectin contamination was further established by immunoblotting (34) with monospecific antibodies. The purified fibrinogen was at least 92% clottable.
vWF was purified following methods previously described in detail (2, 35, 36) . Analysis of the purified vWF by 5% polyacrylamide (5% cross-linking) slab gel electrophoresis in the presence of SDS and under reducing conditions demonstrated one major band of apparent Mr = 220,000. In particular, no fibrinogen was detected in the vWF preparations (2). Absence of fibrinogen and fibronectin contamination was further established by immunoblotting with monospecific antibodies. All preparations of purified vWF had > 100 U of ristocetin cofactor activity and vWF antigen per milligram of protein, and had a multimeric structure like that of plasma vWF (2). Radioiodination ofproteins. Purified proteins were radiolabeled with carrier-free Na'251 (Amersham Corp.) using Iodogen (Pierce Chemical Co., Rockford, IL), as described by Fraker and Speck (37) . All radiolabeled proteins were analyzed by polyacrylamide gel electrophoresis and showed no structural alterations as compared to the unlabeled counterparts. Specific activity was between 0.4 and 1.2 mCi/mg of protein for all ligands. Radioactivity was over 90% precipitable in 10% trichloroacetic acid in all cases.
Binding studies. The binding of radiolabeled anti-GPIIb/IIIa Fab to platelets was tested with both platelet-rich plasma and washed suspensions. Fab and platelets (final count between 0.3 and 1 X 108/ml) were incubated for 30 min at 22-250C, and platelets were then separated from the reaction mixture by layering duplicate aliquots of the latter onto 20% sucrose in a microcentrifuge tube (2) . After centrifugation at 13,000 g for 4 min (Beckman Instruments, Inc., Fullerton, CA), the tip of the tubes containing the pelleted platelets was cut with a scalpel and the platelet-bound radioactivity counted in a gamma-scintillation counter (Packard Instrument Co., Inc., Downers Grove, IL). Nonspecific binding was determined in the presence of at least a 20-fold excess of the correspondent unlabeled Fab and never exceeded 10% oftotal binding. The number ofantibody molecules bound per platelet was estimated by measuring binding at antibody concentrations where a twofold increase in concentration gave <5% increase in binding. The (39) , using free Ca2+ concentrations, in EGTA buffer, between 1O-6 and I0-, M. For these studies, washed platelets devoid of calcium were prepared as described above (29), with the exception that the final suspension contained 1 mM Mg2+ and was incubated with 1 mM acetylsalicilic acid for 30 min at room temperature before use.
Results
The two new anti-platelet monoclonal antibodies here described were designated LJP5 and LJP9. In crossed immunoelectrophoresis, they reacted against the membrane GPIIb/IIIa complex ( Fig. 1 ), but not against dissociated GPIIb/IIIa or GPIIIa (Fig.  2) . Furthermore, immunoisolation studies using surface-labeled platelets demonstrated that both LJP5 and UP9 reacted with two proteins exhibiting apparent molecular weight correspondent to that of GPIIb and GPIIIa (Fig. 3) . The same proteins reacted with AP2, a well-characterized anti-GPIIb/IIIa monoclonal antibody (19, 37) .
Monovalent Fab fragment of both UP5 and LJP9 bound to unstimulated human platelets in a saturable manner (Fig. 4) (Fig. 4) . On the other hand, UP9 inhibited the binding of LJP5 and vice versa, and results were compatible with a mechanism of competitive inhibition (Fig. 4) . The The binding of vWF to ADP-stimulated platelets was completely blocked by LJP5 as well as LJP9 (Fig. 5, upper panel) . The latter antibody also blocked the binding of fibrinogen, whereas LJP5 had no effect in this regard (Fig. 5, lower panel) . Similar results were obtained with thrombin-stimulated platelets. The amount of each antibody necessary to achieve maximal inhibitory effect was in agreement with the amount that gave saturation of binding to platelets (compare Fig. 4 and Fig. 5 ). Nevertheless, UP5 Fab had no effect on fibrinogen binding even when added in a 10-fold excess over the saturating amounts. Fig. 1 6). This was consistently observed at all Fab concentrations tested, using a constant 125I-vWF concentration, thus demonstrating that the effect of UP5 Fab on vWF binding was not related to alterations induced in the vWF molecule, but rather to occupancy of the corresponding epitope on GPIIb/IIIa. As shown in Fig. 4 , excess UP5 could block LJP9 binding to platelets. Accordingly, excess UPS Fab could effectively prevent the inhibitory effect of WP9 Fab on fibrinogen binding (Fig. 7) . Moreover, LIPS Fab had no effect on ADP-induced platelet aggregation, whereas LJP9 Fab completely inhibited it (Fig. 8) . Identical results were observed when a-thrombin or collagen were used as agonists instead of ADP. In accordance with the results of fibrinogen binding studies, excess LJP5 Fab could prevent the inhibitory effect of LJP9 on aggregation (Fig.  8) . The results of aggregation studies were identical for either citrated platelet-rich plasma or washed platelet suspensions containing purified fibrinogen and 2 mM CaCl2.
DiscUssion
Our results demonstrate that the two new monoclonal antiplatelet antibodies described in this report, LJP5 and LP9, recognize distinct epitopes on the GPIIb/IIIa complex that are also different from the one recognized by AP2. In fact, LJP9 and AP2 bound to platelets independently of each other, whereas UP5 and AP2 competed for binding. Competition for binding was also observed between LJP5 and UP9. The most likely explanation for our findings is that the epitope recognized by 10 -o (x, 6 i&g/ml; o, 1.5 ug/ml). The intersect on the yaxis was not significantly changed in the presence of the competing antibody, whereas the intersect on the x-axis shifted towards the origin. These results are compatible with a competitive mechanism of inhibition.
LIP5 overlaps with both those recognized by AP2 and LJP9, whereas the latter two do not overlap. Of course, the resolution of these inhibition binding studies is limited by the size of the Platelets were stimulated with thrombin in the presence of EDTA for 10 min, then hirudin was added followed by the radiolabeled ligands (see Methods). All incubations were at room temperature (22-250C) and the pH of the mixtures was 7.4. UP5 and LJP9 were added at a concentration of 6 ,g/ml (1.2 X 10-7 M), fibrinogen was at 60 ,g/ml, and vWF at 5 Mg/ml. Binding defined as 100% corresponded to that shown in Fig. 4 for the two antibodies, to 64,000 molecules/platelet for fibrinogen, and to 1.2 ug/108 platelets for vWF. platelets. These results may reflect technical variability of the assays, but are also likely to reflect individual variations in the number ofGPIIb/IIIa molecules expressed on the platelet membrane. In our studies, we used monovalent Fab rather than divalent IgG (40, 41, 43, 44) or F(ab')2 (42) . This may be responsible, at least in part, for some of the differences observed, since antibodies may bind to cell surface antigens divalently, and the proportion of divalent to monovalent binding may vary (45, 46) . The reason why thrombin-stimulated platelets bound up to 50% more LJP5 and LJP9 Fab than unstimulated platelets may reflect the fact that a pool of GPIIb/IIIa molecules contained in the a-granule membrane becomes exposed on the platelet surface following secretion (47) fibrinogen binding site(s) . However, they might also reflect the fact that calcium-dependent and stimulation-dependent changes in the microenvironment surrounding the GPIIb/ Ilia complex are necessary for the binding ofvWF and fibrinogen, but not of LJP5 and LJP9, possibly because of the larger size of the two adhesive glycoproteins as compared to the antibody molecules (53) . The observations that smaller peptides derived from the fibrinogen y chain bind to unstimulated platelets (54) , and that fibrinogen itself forms a complex with isolated GPIIb/ IlIa (8) , are both in agreement with the latter hypothesis. Therefore, because vWF is obviously a much larger molecule than fibrinogen, it is possible that the steric constraints imposed by LJP5 on the microenvironment surrounding GPIIb/IIIa are less tight than those imposed by LJP9, so that only binding of the large vWF, but not fibrinogen, is affected by the former antibody. Both LJP5 and LJP9 interfered with the association of calcium with the membrane of unstimulated platelets, but only partially and to about the same extent. Therefore, changes in the Ca2" associated with the GPIIb/IIIa complex are not likely to explain the different effect of the two antibodies on vWF and fibrinogen binding.
In conclusion, the present study demonstrates that the binding of at least two different adhesive glycoproteins to stimulated platelets can be independently modulated. This concept should prove important for unraveling the molecular bases of platelet interaction with specific ligands and for better understanding the mechanisms of platelet function.
